Description

Product Description

Sunitinib Malate is a synthetic multi-targeted tyrosine kinase inhibitor primarily designed to block receptor tyrosine kinases such as VEGFR, PDGFR, FLT3, and KIT. It is supplied in capsule form for laboratory research, allowing controlled dosing and easy administration in preclinical models. With high receptor affinity and broad kinase inhibition, Sunitinib Malate is widely used in research studying angiogenesis, tumor growth regulation, and resistance mechanisms in oncology.

In cellular and in vivo studies, Sunitinib Malate suppresses endothelial proliferation, migration, and survival by blocking VEGFR and PDGFR autophosphorylation. These pathways are essential in tumor vascular development and maintenance. By inhibiting multiple kinases, it provides researchers with a model compound to investigate tumor angiogenesis suppression, apoptosis induction, and cell cycle arrest mechanisms.

Product Specifications

Mechanism of Action

Sunitinib Malate acts by competitively inhibiting ATP binding at the catalytic sites of receptor tyrosine kinases, including VEGFR, PDGFR, and c-KIT. This inhibition halts receptor phosphorylation and downstream signal transduction involved in angiogenesis and cell proliferation.

The compound effectively disrupts signaling through the MAPK and PI3K/AKT pathways, leading to growth inhibition, apoptosis induction, and reduced endothelial migration. Its ability to target multiple kinases simultaneously makes it an ideal model to study cross-talk between angiogenic and proliferative pathways in tumor biology.

Preclinical research often focuses on its dual inhibition of tumor vasculature and cancer cell signaling, exploring Sunitinib Malate as a reference molecule for multi-pathway blockade mechanisms.

Side Effects

In preclinical assays, Sunitinib Malate induces expected VEGFR/PDGFR-related effects such as:

• Inhibition of endothelial proliferation and vessel formation.
• Induction of apoptotic signaling in tumor-associated cells.
• Cell cycle arrest in G1 phase.
• Reduced tumor perfusion and altered oxygenation levels.
• Gene modulation involving VEGF-A, HIF-1α, and BCL-2.

All experimental handling should follow institutional chemical safety protocols.

Keywords

Sunitinib Malate, CAS 341031-54-7, tyrosine kinase inhibitor, VEGFR inhibitor, PDGFR inhibitor, multi-target inhibitor, oncology research chemical, antiangiogenic compound, small molecule inhibitor, research-grade kinase blocker.

Shipping Guarantee

All shipments are transported via validated cold-chain logistics to maintain Sunitinib Malate stability. Packages are sealed with moisture-proof, insulated materials and temperature monitoring. Each delivery is fully insured and traceable through international couriers.

Trade Assurance

Our trade assurance guarantees verified product purity (≥99%) and analytical validation via HPLC, MS, and NMR. Every batch includes a Certificate of Analysis (CoA). Refund or replacement is provided if analytical parameters differ from listed specifications.

Payment Support

We accept flexible and secure payment methods: PayPal, Visa, MasterCard, American Express, bank transfer (T/T), and cryptocurrency (USDT, BTC, ETH). All transactions are protected by encryption and verified payment gateways to ensure confidentiality.

Disclaimer

All products are intended for laboratory research only and not for human or veterinary use. They are not drugs, diagnostics, or medical devices. Researchers must follow institutional biosafety and chemical handling standards.